Ian time for you to progression (1.six versus 1.4 months, HR 0.64; P=0.04) was observed in
Ian time to progression (1.six versus 1.four months, HR 0.64; P=0.04) was observed in favor of tivantinib. Importantly, a prespecified subgroup analysis indicated that MET overexpression may well represent a…